A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle.

Authors: Nehal J. Lakhani, William Bennion McKean, Ildefonso Ismael Rodriguez Rivera, Antonio Giordano, Timothy A. Yap, Afshin Dowlati, Vivek Subbiah, Judy S. Wang, Manali A. Bhave, Kyaw Zin Thein, Jinshu Fang, Eric F. Connor, Li-Fen Liu, Peadar Cremin, Lukas Makris, Li-Pen Ben Tsao, Lisa M. Kopp, Michael Craig Cox, Shivaani Kummar

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3175

Source: Full article

---

Abstract

TPS3175